Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?

J Clin Oncol. 2021 Nov 10;39(32):3541-3545. doi: 10.1200/JCO.21.01059. Epub 2021 Aug 18.
No abstract available

MeSH terms

  • Anthracyclines / adverse effects
  • Anthracyclines / therapeutic use*
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Chemotherapy, Adjuvant
  • Clinical Decision-Making
  • Female
  • Humans
  • Neoadjuvant Therapy* / adverse effects
  • Patient Selection
  • Quality of Life
  • Receptor, ErbB-2 / analysis*
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Anthracyclines
  • Antibiotics, Antineoplastic
  • Biomarkers, Tumor
  • ERBB2 protein, human
  • Receptor, ErbB-2